OncoMatch/Clinical Trials/NCT06471205
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
Is NCT06471205 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including BL-B01D1 and PD-1 Monoclonal Antibody for triple-negative breast cancer.
Treatment: BL-B01D1 · PD-1 Monoclonal Antibody — This phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 combined with PD-1 monoclonal antibody in patients with unresectable locally advanced or recurrent metastatic triple-negative breast cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: antibody-drug conjugate with topoisomerase I inhibitor payload
ADC drugs that have received topoisomerase I inhibitors as small molecule toxins
Cannot have received: checkpoint inhibitor
Exception: prior to neoadjuvant/adjuvant chemotherapy
Patients with checkpoint inhibitors prior to neoadjuvant/adjuvant chemotherapy
Cannot have received: immunomodulatory drug
Use of an immunomodulatory drug within 14 days before the first dose of study drug
Cannot have received: palliative radiotherapy
Palliative radiotherapy within 2 weeks before the first dose
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06471205 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify